All data are based on the daily closing price as of September 15, 2025
g
GNI Group
2160.TSE
17.48 USD
-0.10
-0.57%
Overview
Last close
17.48 usd
Market cap
971.06M usd
52 week high
30.23 usd
52 week low
10.22 usd
Target price
29.18 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
5.9515
Price/Book Value
4.0718
Enterprise Value
888.21M usd
EV/Revenue
5.4235
EV/EBITDA
318.9585
Key financials
Revenue TTM
163.77M usd
Gross Profit TTM
117.44M usd
EBITDA TTM
-1.88M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
470.00M usd
Net debt
-39.30M usd
About
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.